{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:11:42Z","timestamp":1787235102650,"version":"build-2736575974"},"reference-count":163,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>When sarcoidosis needs treatment, pharmacotherapy is usually required. Although glucocorticoids work reliably and relatively quickly for sarcoidosis, these drugs are associated with numerous significant side effects. Such side effects are common in sarcoidosis patients, as the disease frequently has a chronic course and glucocorticoid treatment courses are often prolonged. For these reasons, corticosteroid-sparing and corticosteroid-replacing therapies are often required for sarcoidosis. Unfortunately, many healthcare providers who care for sarcoidosis patients are not familiar with the use of these agents. In this manuscript, we provide a review of the pharmacotherapy of sarcoidosis. We discuss the mechanism of action, dosing, side-effect profile, approach to monitoring and patient counselling concerning glucocorticoids, and the common alternative drugs recommended for use in the recent European Respiratory Society (Lausanne, Switzerland) Sarcoidosis Treatment Guidelines. We also discuss the use of these agents in special situations including hepatic insufficiency, renal insufficiency, pregnancy, breastfeeding, vaccination, and drug\u2013drug interactions. It is hoped that this manuscript will provide valuable practical guidance to clinicians who care for sarcoidosis patients.<\/jats:p>","DOI":"10.3390\/jcm13051250","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T08:34:35Z","timestamp":1708590875000},"page":"1250","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Pharmacology in Sarcoidosis: How to Use and Monitor Sarcoidosis Medications"],"prefix":"10.3390","volume":"13","author":[{"given":"Sooyeon","family":"Kwon","sequence":"first","affiliation":[{"name":"Samuel S. Stratton Veterans Affairs Medical Center, Albany, NY 12208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4663-7985","authenticated-orcid":false,"given":"Marc A.","family":"Judson","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, NY 12208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_2","unstructured":"Brunton, L.L., and Knollmann, B.C. (2023). Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics, McGraw-Hill Education. [14th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.rdc.2015.08.012","article-title":"Corticosteroids in Sarcoidosis","volume":"42","author":"Judson","year":"2016","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"ref_4","unstructured":"Vanderah, T.W. (2024). Katzung\u2019s Basic & Clinical Pharmacology, McGraw-Hill. [16th ed.]."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"106081","DOI":"10.1016\/j.rmed.2020.106081","article-title":"Corticosteroid refractory sarcoidosis","volume":"171","author":"Goldman","year":"2020","journal-title":"Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/art.42646","article-title":"2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_8","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-4632.2009.04322.x","article-title":"Prevention and treatment of systemic glucocorticoid side effects","volume":"49","author":"Werth","year":"2010","journal-title":"Int. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1710-1492-7-13","article-title":"Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy","volume":"7","author":"Ahmet","year":"2011","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients with Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10067-003-0732-3","article-title":"Bilateral Achilles tendinitis with spontaneous rupture induced by levofloxacin in a patient with systemic sclerosis","volume":"22","author":"Mejia","year":"2003","journal-title":"Clin. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/jps.2600670746","article-title":"Effect of concomitant administration of magnesium trisilicate on GI absorption of dexamethasone in humans","volume":"67","author":"Naggar","year":"1978","journal-title":"J. Pharm. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0016-5085(81)90122-0","article-title":"Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers","volume":"80","author":"Uribe","year":"1981","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00630299","article-title":"Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone","volume":"26","author":"Albin","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2125.1979.tb00952.x","article-title":"Concurrent administration of antacids and prednisone: Effect on serum levels of prednisolone","volume":"7","author":"Tanner","year":"1979","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1345\/aph.1H418","article-title":"Effect of oral corticosteroids on chronic warfarin therapy","volume":"40","author":"Hazlewood","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/clpt.1987.173","article-title":"Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy","volume":"42","author":"Bartoszek","year":"1987","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/bmj.286.6369.923","article-title":"Rifampicin reduces effectiveness and bioavailability of prednisolone","volume":"286","author":"McAllister","year":"1983","journal-title":"Br. Med. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/archinte.1994.00420130119015","article-title":"Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment","volume":"154","author":"Carrie","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"(1995). Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. JAMA, 273, 413\u2013418.","DOI":"10.1001\/jama.273.5.413"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1096-9926(199711)56:5<335::AID-TERA7>3.0.CO;2-W","article-title":"Population-based case-control study of teratogenic potential of corticosteroids","volume":"56","author":"Czeizel","year":"1997","journal-title":"Teratology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z","article-title":"Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies","volume":"62","author":"Mazzotta","year":"2000","journal-title":"Teratology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.2174\/138161210793797898","article-title":"Use of glucocorticoids in pregnancy","volume":"16","author":"Lunghi","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/bdra.10134","article-title":"First trimester exposure to corticosteroids and oral clefts","volume":"67","author":"Pradat","year":"2003","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nrrheum.2009.103","article-title":"Management of RA medications in pregnant patients","volume":"5","author":"Ostensen","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1901208","DOI":"10.1183\/13993003.01208-2019","article-title":"ERS\/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases","volume":"55","author":"Middleton","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"152106","DOI":"10.1016\/j.semarthrit.2022.152106","article-title":"Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus","volume":"57","author":"Boone","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e13587","DOI":"10.1111\/ctr.13587","article-title":"Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Fishman","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/hematology.2020000116","article-title":"Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases","volume":"2020","author":"Malpica","year":"2020","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"ref_31","unstructured":"Mazurek, G.H., Jereb, J.A., Vernon, A., LoBue, P., Goldberg, S., and Castro, K.G. (2010). Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection\u2014United States, 2010, Centers for Disease Control and Prevention."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.arbres.2022.01.011","article-title":"Clinical and Epidemiological Correlates of Low IFN-Gamma Responses in Mitogen Tube of QuantiFERON Assay in Tuberculosis Infection Screening During the COVID-19 Pandemic: A Population-Based Marker of COVID-19 Mortality?","volume":"58","author":"Balbin","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_33","first-page":"61","article-title":"The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation","volume":"12","author":"Hakimian","year":"2018","journal-title":"Biologics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.cgh.2017.11.038","article-title":"Factors That Contribute to Indeterminate Results from the QuantiFERON-TB Gold In-Tube Test in Patients with Inflammatory Bowel Disease","volume":"16","author":"Kaur","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res."},{"key":"ref_36","unstructured":"Altered Immunocompetence (2023, November 20). General Best Practice Guidelines for Immunization. Available online: https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/immunocompetence.html."},{"key":"ref_37","unstructured":"(2023, November 20). Shingrix. Available online: https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/shingrix\/faqs.html."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/0003-4819-103-4-489","article-title":"Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study","volume":"103","author":"Andersen","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.1780280702","article-title":"Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial","volume":"28","author":"Williams","year":"1985","journal-title":"Arthritis Rheum."},{"key":"ref_41","first-page":"760","article-title":"A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis","volume":"11","author":"Thompson","year":"1984","journal-title":"J. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archinte.1995.00430080088011","article-title":"Prolonged use of methotrexate for sarcoidosis","volume":"155","author":"Lower","year":"1995","journal-title":"Arch. Intern. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/ndt\/gfac219","article-title":"Renal sarcoidosis","volume":"38","author":"Mehta","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1590\/abd1806-4841.20186687","article-title":"Methotrexate-induced mucositis with extra-mucosal involvement after acidental overdose","volume":"93","author":"Rampon","year":"2018","journal-title":"An. Bras. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study","volume":"44","author":"Laan","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_47","first-page":"563","article-title":"Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate","volume":"32","author":"Pichlmeier","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jps.2600780219","article-title":"Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients","volume":"78","author":"Herman","year":"1989","journal-title":"J. Pharm. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2014-206504","article-title":"The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis","volume":"75","author":"Hazlewood","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0305-7372(95)90010-1","article-title":"Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function","volume":"21","author":"Kintzel","year":"1995","journal-title":"Cancer Treat. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/ndt\/17.3.530","article-title":"Should low-dose methotrexate therapy be prescribed to dialysis patients?","volume":"17","author":"Basile","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cpt197823168","article-title":"Effect of pleural effusion on high-dose methotrexate kinetics","volume":"23","author":"Evans","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"833","DOI":"10.7326\/0003-4819-121-11-199412010-00002","article-title":"Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial","volume":"121","author":"Morgan","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_54","first-page":"324","article-title":"Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis","volume":"32","author":"Davis","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res"},{"key":"ref_56","unstructured":"Hanoodi, M., and Mittal, M. (2024). Methotrexate, StatPearls."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/rheumatology\/37.1.105","article-title":"Methotrexate and trimethoprim: A fatal interaction","volume":"37","author":"Steuer","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"261","DOI":"10.7326\/0003-4819-111-3-261_1","article-title":"Pancytopenia and methotrexate with trimethoprim-sulfamethoxazole","volume":"111","author":"Jeurissen","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/art.1780290118","article-title":"Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment","volume":"29","author":"Maricic","year":"1986","journal-title":"Arthritis Rheum."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"780","DOI":"10.7326\/0003-4819-94-6-780","article-title":"Acute megaloblastic anemia induced by high-dose trimethoprim-sulfamethoxazole","volume":"94","author":"Kobrinsky","year":"1981","journal-title":"Ann. Intern. Med."},{"key":"ref_61","first-page":"440","article-title":"Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole","volume":"13","author":"Thomas","year":"1986","journal-title":"J. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e15945","DOI":"10.1111\/dth.15945","article-title":"Fatal low-dose methotrexate toxicity: A case report and literature review","volume":"35","author":"Ouellette","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_63","first-page":"53","article-title":"Methotrexate and trimethoprim-sulfamethoxazole: Toxicity from this combination continues to occur","volume":"60","author":"Cudmore","year":"2014","journal-title":"Can. Fam. Physician"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Mantadakis, E. (2020). Pneumocystis jirovecii Pneumonia in Children with Hematological Malignancies: Diagnosis and Approaches to Management. J. Fungi, 6.","DOI":"10.3390\/jof6040331"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MPH.0000000000000804","article-title":"Efficacy and Safety of Dapsone Versus Trimethoprim\/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children with Acute Lymphoblastic Leukemia with a Background of Ethnic Neutropenia","volume":"39","author":"Nazir","year":"2017","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00007611-199004000-00010","article-title":"Clindamycin\/primaquine therapy and secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS","volume":"83","author":"Kay","year":"1990","journal-title":"South. Med. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.dld.2017.01.141","article-title":"Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)","volume":"49","author":"Biancone","year":"2017","journal-title":"Dig. Liver Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.semarthrit.2018.01.006","article-title":"Paternal exposure to antirheumatic drugs-What physicians should know: Review of the literature","volume":"48","author":"Micu","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/rheumatology\/ket390","article-title":"No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: An observational cohort study","volume":"53","author":"Hoeltzenbein","year":"2014","journal-title":"Rheumatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3899\/jrheum.100600","article-title":"Paternal exposure to methotrexate and pregnancy outcomes","volume":"38","author":"Beghin","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/AOG.0000000000001936","article-title":"Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before Pregnancy","volume":"129","author":"Eck","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/s41598-022-05644-7","article-title":"Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels","volume":"12","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/00003088-200241060-00003","article-title":"Clinical pharmacokinetics of leflunomide","volume":"41","author":"Rozman","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","author":"Sahoo","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_77","unstructured":"(2023, November 20). Leflunomide (Araba) Prescribing Information. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020905s022lbl.pdf."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, Clinical Practice Guideline Panel, and EASL Governing Board Representative (2019). EASL Clinical Practice Guidelines: Drug-induced liver injury. J. Hepatol., 70, 1222\u20131261.","DOI":"10.1016\/j.jhep.2019.02.014"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.chest.2022.06.042","article-title":"Drug-Drug Interactions in the Management of Patients with Pulmonary Arterial Hypertension","volume":"162","author":"Wu","year":"2022","journal-title":"Chest"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0091270009340418","article-title":"Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers","volume":"50","author":"Skerjanec","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1124\/dmd.116.070375","article-title":"Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone","volume":"44","author":"Itkonen","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1592\/phco.26.6.868","article-title":"Leflunomide and warfarin interaction: Case report and review of the literature","volume":"26","author":"Chonlahan","year":"2006","journal-title":"Pharmacotherapy"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/bmj.325.7376.1333","article-title":"Leflunomide can potentiate the anticoagulant effect of warfarin","volume":"325","author":"Lim","year":"2002","journal-title":"BMJ"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/art.27358","article-title":"Birth outcomes in women who have taken leflunomide during pregnancy","volume":"62","author":"Chambers","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_85","unstructured":"(2023, November 23). Leflunomide (Arava). Available online: https:\/\/mothertobaby.org\/fact-sheets\/leflunomide-pregnancy\/."},{"key":"ref_86","unstructured":"(2023, November 23). Clinical Pharmacology and Biopharmaceuticas Reviews. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/20905_arava_biopharmr.pdf."},{"key":"ref_87","unstructured":"Nouri, K. (2023). Skin Cancer: A Comprehensive Guide, McGraw-Hill Education."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ccm.2015.08.009","article-title":"Ocular Sarcoidosis","volume":"36","author":"Pasadhika","year":"2015","journal-title":"Clin. Chest Med."},{"key":"ref_89","unstructured":"(2023, November 25). Azathioprine (Imuran). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/016324s039lbl.pdf."},{"key":"ref_90","unstructured":"Azathioprine (2023, November 25). Lexicomp Online. Waltham, MA: UpToDate, Inc. Available online: https:\/\/online.lexi.com."},{"key":"ref_91","unstructured":"Pratt, V.M., Scott, S.A., Pirmohamed, M., Esquivel, B., Kattman, B.L., and Malheiro, A.J. (2012). Medical Genetics Summarie, National Center for Biotechnology Information."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/jdv.16025","article-title":"Cutaneous squamous cell carcinoma (cSCC) and immunosurveillance\u2014The impact of immunosuppression on frequency of cSCC","volume":"33","author":"Plasmeijer","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_95","first-page":"713","article-title":"The New Pregnancy and Lactation Labeling Rule","volume":"41","author":"Pernia","year":"2016","journal-title":"Pharm. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/ecco-jcc\/jjv118","article-title":"Treating Inflammatory Bowel Disease in Pregnancy: The Issues We Face Today","volume":"9","author":"Damas","year":"2015","journal-title":"J. Crohns Colitis"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.crohns.2010.10.005","article-title":"Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding","volume":"5","author":"Angelberger","year":"2011","journal-title":"J. Crohns Colitis"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohn\u2019s disease: Special situations","volume":"4","author":"Dignass","year":"2010","journal-title":"J. Crohns Colitis"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1136\/gutjnl-2016-312123","article-title":"Reassuring results on birth outcomes in children fathered by men treated with azathioprine\/6-mercaptopurine within 3 months before conception: A nationwide cohort study","volume":"66","author":"Norgard","year":"2017","journal-title":"Gut"},{"key":"ref_101","unstructured":"DiPiro, J.T., Yee, G.C., Haines, S.T., Nolin, T.D., Ellingrod, V.L., and Posey, L.M. (2023). DiPiro\u2019s Pharmacotherapy: A Pathophysiologic Approach, McGraw Hill. [12th ed.]."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bpobgyn.2019.09.002","article-title":"Pregnancy and Systemic Lupus Erythematosus","volume":"64","author":"Petri","year":"2020","journal-title":"Best. Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_104","unstructured":"(2023, November 26). Mycophenolate Mofetil (Cellcept). Available online: https:\/\/www.gene.com\/download\/pdf\/cellcept_prescribing.pdf."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/1744666X.2016.1212659","article-title":"Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus","volume":"13","author":"Mok","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1093\/ndt\/gfh446","article-title":"The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation","volume":"19","author":"Pieper","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0091270004271555","article-title":"The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil","volume":"45","author":"Naderer","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/FTD.0b013e31803111d5","article-title":"The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation","volume":"29","author":"Borrows","year":"2007","journal-title":"Ther. Drug. Monit."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clpt.2006.08.002","article-title":"Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients","volume":"80","author":"Naesens","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/0971-4065.62091","article-title":"Mycophenolic acid area under the curve recovery time following rifampicin withdrawal","volume":"20","author":"Annapandian","year":"2010","journal-title":"Indian J. Nephrol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clpt.2005.03.004","article-title":"Drug interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphate-glucuronosyltransferase","volume":"78","author":"Kuypers","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit"},{"key":"ref_114","unstructured":"Vanderah, T.W. (2024). Katzung\u2019s Basic & Clinical Pharmacology, McGraw-Hill. [16th ed.]."},{"key":"ref_115","unstructured":"Vanderah, T.W. (2024). Katzung\u2019s Basic & Clinical Pharmacology, McGraw-Hill. [16th ed.]."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3899\/jrheum.110959","article-title":"Cardiomyopathy caused by longterm treatment with chloroquine: A rare disease, or a rare diagnosis?","volume":"39","author":"Tonnesmann","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/11536520-000000000-00000","article-title":"Medications and glucose-6-phosphate dehydrogenase deficiency: An evidence-based review","volume":"33","author":"Youngster","year":"2010","journal-title":"Drug Saf."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s40800-017-0048-x","article-title":"Psychomotor Agitation Following Treatment with Hydroxychloroquine","volume":"4","author":"Manzo","year":"2017","journal-title":"Drug Saf. Case Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10787-018-0498-5","article-title":"Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: A review article","volume":"26","author":"Mascolo","year":"2018","journal-title":"Inflammopharmacology"},{"key":"ref_121","first-page":"195","article-title":"Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis","volume":"26","author":"Shojania","year":"1999","journal-title":"J. Rheumatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/rheumatology\/kem378","article-title":"Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA","volume":"47","author":"Cansu","year":"2008","journal-title":"Rheumatology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI0214955","article-title":"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes","volume":"109","author":"Hundal","year":"2002","journal-title":"J. Clin. Invest."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2337\/diacare.5.1.64","article-title":"Salicylates as hypoglycemic agents","volume":"5","author":"Baron","year":"1982","journal-title":"Diabetes Care"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.0954-6820.1982.tb01971.x","article-title":"Digoxin-hydroxychloroquine interaction?","volume":"211","author":"Leden","year":"1982","journal-title":"Acta Med. Scand"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2165\/00003088-199325050-00005","article-title":"Clinical pharmacokinetics of slow-acting antirheumatic drugs","volume":"25","author":"Tett","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1183\/09031936.03.00083002","article-title":"Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis","volume":"21","author":"Fehrenbach","year":"2003","journal-title":"Eur. Respir. J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0954-6111(98)90085-3","article-title":"Sarcoidosis: Historical perspective and immunopathogenesis (Part I)","volume":"92","author":"Zissel","year":"1998","journal-title":"Respir. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1529-8019.2007.00138.x","article-title":"TNF- alpha inhibitors","volume":"20","author":"Jackson","year":"2007","journal-title":"Dermatol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1378\/chest.08-1347","article-title":"The treatment of lupus pernio: Results of 116 treatment courses in 54 patients","volume":"135","author":"Stagaki","year":"2009","journal-title":"Chest"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"107004","DOI":"10.1016\/j.rmed.2022.107004","article-title":"Outcomes of prednisone-tapering regimens for cardiac sarcoidosis: A retrospective analysis demonstrating a benefit of infliximab","volume":"203","author":"Judson","year":"2022","journal-title":"Respir. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/acn3.51968","article-title":"Infliximab in neurosarcoidosis: A systematic review and meta-analysis","volume":"11","author":"Chaiyanarm","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e847","DOI":"10.1212\/NXI.0000000000000847","article-title":"Infliximab treatment in pathology-confirmed neurosarcoidosis","volume":"7","author":"Fritz","year":"2020","journal-title":"Neurol. Neuroimmunol Neuroinflamm"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B Reactivation Associated with Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/ard.2010.148783","article-title":"Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy","volume":"70","author":"Lan","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ccm.2019.07.003","article-title":"Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor-\u03b1 and Beyond","volume":"40","author":"Godfrey","year":"2019","journal-title":"Clin. Chest. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3899\/jrheum.150057","article-title":"The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-\u03b1 Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry\/Cohort Studies","volume":"42","author":"Ai","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of TNF-Inhibitors","volume":"11","author":"Atiqi","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis","volume":"72","author":"Garces","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: Relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1097\/01.MIB.0000435435.91988.b6","article-title":"The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies","volume":"19","author":"Yanai","year":"2013","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn\u2019s disease: A prospective cohort study","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756284821997794","article-title":"Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A hospital-based cohort study from Korea","volume":"14","author":"Choi","year":"2021","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.gtc.2014.05.002","article-title":"Miscellaneous adverse events with biologic agents (excludes infection and malignancy)","volume":"43","author":"Feuerstein","year":"2014","journal-title":"Gastroenterol. Clin. North Am."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: Long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/1352458519828601","article-title":"Iatrogenic CNS demyelination in the era of modern biologics","volume":"25","author":"Kumar","year":"2019","journal-title":"Mult. Scler."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1517\/14740338.2013.755957","article-title":"Selective TNF-alpha inhibitor-induced injection site reactions","volume":"12","author":"Murdaca","year":"2013","journal-title":"Expert Opin. Drug. Saf."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/cld.1005","article-title":"The Impact of Biologics for the Management of Inflammatory Bowel Disease on Liver Enzymes","volume":"16","author":"Aby","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_153","unstructured":"Infliximab (2012). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Sell, S., and Max, E.E. (2001). Immunology, Immunopathology, and Immunity, ASM Press. [6th ed.].","DOI":"10.1128\/9781555818012"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1172\/JCI110036","article-title":"Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes","volume":"67","author":"Hunninghake","year":"1981","journal-title":"J. Clin. Invest."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1183\/09031936.00080209","article-title":"Rituximab-induced lung disease: A systematic literature review","volume":"35","author":"Liote","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fendo.2013.00009","article-title":"The melanocortin receptors and their accessory proteins","volume":"4","author":"Ramachandrappa","year":"2013","journal-title":"Front. Endocrinol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"bqac083","DOI":"10.1210\/endocr\/bqac083","article-title":"The Multifaceted Melanocortin Receptors","volume":"163","author":"Laiho","year":"2022","journal-title":"Endocrinology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3389\/fendo.2019.00683","article-title":"Melanocortin Regulation of Inflammation","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s41030-022-00181-0","article-title":"Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review","volume":"8","author":"Mirsaeidi","year":"2022","journal-title":"Pulm. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1055\/s-0037-1602589","article-title":"Quality of Life in Sarcoidosis","volume":"38","author":"Judson","year":"2017","journal-title":"Semin. Respir Crit. Care Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/5\/1250\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:03:12Z","timestamp":1760104992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/5\/1250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":163,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jcm13051250"],"URL":"https:\/\/doi.org\/10.3390\/jcm13051250","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}